Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibi...
Gespeichert in:
| Veröffentlicht in: | Signal transduction and targeted therapy 2020-11, Vol.5 (1), p.270-270, Article 270 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 270 |
|---|---|
| container_issue | 1 |
| container_start_page | 270 |
| container_title | Signal transduction and targeted therapy |
| container_volume | 5 |
| creator | Chen, Miaoqin Hu, Shiman Li, Yiling Jiang, Ting Ting Jin, Hongchuan Feng, Lifeng |
| description | Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibitors. In this review, we summarized the latest discoveries on the combination of nucleic acid-sensing immunity and immune checkpoint inhibitors in cancer immunotherapy. Given the critical role of nuclear acid-mediated immunity in maintaining the activation of T cell function, it seems that harnessing the nuclear acid-mediated immunity opens up new strategies to enhance the effect of immune checkpoint inhibitors for tumor control. |
| doi_str_mv | 10.1038/s41392-020-00347-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7677403</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2463107384</sourcerecordid><originalsourceid>FETCH-LOGICAL-c512t-1c45640f7b4d93c1370e80b919a434e6b15e27ac6aec00698af268cbfa82c6fa3</originalsourceid><addsrcrecordid>eNp9kU9r3DAQxUVpaUKaL9BD8TEXN6M_luxLIYSmCQRySaA3MdaOd5Xa8laSC_vtq9ZJSC89adB782aYH2MfOXzmINvzpLjsRA0CagCpTN29YccCmq6WWjZvX9VH7DSlRwDgWhrTqPfsSErBVaOaY_b9HuOWsg_bKixuJIwVOr-pJ9p4zLSp_DQtwedD5UPlMDiK6xdVbkfux372IRdt53uf51jlHUXce0of2LsBx0SnT-8Je7j6en95Xd_efbu5vLitXcNFrrlTjVYwmF5tOum4NEAt9B3vUElFuucNCYNOIzkA3bU4CN26fsBWOD2gPGFf1tz90pelHYUccbT76CeMBzujt_8qwe_sdv5ljTZGgSwBZ08Bcf65UMp28snROGKgeUlWKC05GNmqYhWr1cU5pUjDyxgO9g8Vu1KxhYr9S8V2penT6wVfWp4ZFINcDalIYUvRPs5LDOVo_4v9Dc3LmkI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2463107384</pqid></control><display><type>article</type><title>Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Chen, Miaoqin ; Hu, Shiman ; Li, Yiling ; Jiang, Ting Ting ; Jin, Hongchuan ; Feng, Lifeng</creator><creatorcontrib>Chen, Miaoqin ; Hu, Shiman ; Li, Yiling ; Jiang, Ting Ting ; Jin, Hongchuan ; Feng, Lifeng</creatorcontrib><description>Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibitors. In this review, we summarized the latest discoveries on the combination of nucleic acid-sensing immunity and immune checkpoint inhibitors in cancer immunotherapy. Given the critical role of nuclear acid-mediated immunity in maintaining the activation of T cell function, it seems that harnessing the nuclear acid-mediated immunity opens up new strategies to enhance the effect of immune checkpoint inhibitors for tumor control.</description><identifier>ISSN: 2059-3635</identifier><identifier>ISSN: 2095-9907</identifier><identifier>EISSN: 2059-3635</identifier><identifier>DOI: 10.1038/s41392-020-00347-9</identifier><identifier>PMID: 33214545</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1059 ; 631/67/580 ; Cancer Research ; Cell Biology ; Humans ; Immune Checkpoint Inhibitors - therapeutic use ; Immunity, Cellular - drug effects ; Internal Medicine ; Lymphocyte Activation - drug effects ; Medicine ; Medicine & Public Health ; Neoplasms - drug therapy ; Neoplasms - immunology ; Nucleic Acids - immunology ; Oncology ; Pathology ; Review ; Review Article ; T-Lymphocytes - immunology</subject><ispartof>Signal transduction and targeted therapy, 2020-11, Vol.5 (1), p.270-270, Article 270</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c512t-1c45640f7b4d93c1370e80b919a434e6b15e27ac6aec00698af268cbfa82c6fa3</citedby><cites>FETCH-LOGICAL-c512t-1c45640f7b4d93c1370e80b919a434e6b15e27ac6aec00698af268cbfa82c6fa3</cites><orcidid>0000-0003-4506-1213</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677403/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677403/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33214545$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Miaoqin</creatorcontrib><creatorcontrib>Hu, Shiman</creatorcontrib><creatorcontrib>Li, Yiling</creatorcontrib><creatorcontrib>Jiang, Ting Ting</creatorcontrib><creatorcontrib>Jin, Hongchuan</creatorcontrib><creatorcontrib>Feng, Lifeng</creatorcontrib><title>Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies</title><title>Signal transduction and targeted therapy</title><addtitle>Sig Transduct Target Ther</addtitle><addtitle>Signal Transduct Target Ther</addtitle><description>Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibitors. In this review, we summarized the latest discoveries on the combination of nucleic acid-sensing immunity and immune checkpoint inhibitors in cancer immunotherapy. Given the critical role of nuclear acid-mediated immunity in maintaining the activation of T cell function, it seems that harnessing the nuclear acid-mediated immunity opens up new strategies to enhance the effect of immune checkpoint inhibitors for tumor control.</description><subject>631/67/1059</subject><subject>631/67/580</subject><subject>Cancer Research</subject><subject>Cell Biology</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Immunity, Cellular - drug effects</subject><subject>Internal Medicine</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - immunology</subject><subject>Nucleic Acids - immunology</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Review</subject><subject>Review Article</subject><subject>T-Lymphocytes - immunology</subject><issn>2059-3635</issn><issn>2095-9907</issn><issn>2059-3635</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU9r3DAQxUVpaUKaL9BD8TEXN6M_luxLIYSmCQRySaA3MdaOd5Xa8laSC_vtq9ZJSC89adB782aYH2MfOXzmINvzpLjsRA0CagCpTN29YccCmq6WWjZvX9VH7DSlRwDgWhrTqPfsSErBVaOaY_b9HuOWsg_bKixuJIwVOr-pJ9p4zLSp_DQtwedD5UPlMDiK6xdVbkfux372IRdt53uf51jlHUXce0of2LsBx0SnT-8Je7j6en95Xd_efbu5vLitXcNFrrlTjVYwmF5tOum4NEAt9B3vUElFuucNCYNOIzkA3bU4CN26fsBWOD2gPGFf1tz90pelHYUccbT76CeMBzujt_8qwe_sdv5ljTZGgSwBZ08Bcf65UMp28snROGKgeUlWKC05GNmqYhWr1cU5pUjDyxgO9g8Vu1KxhYr9S8V2penT6wVfWp4ZFINcDalIYUvRPs5LDOVo_4v9Dc3LmkI</recordid><startdate>20201120</startdate><enddate>20201120</enddate><creator>Chen, Miaoqin</creator><creator>Hu, Shiman</creator><creator>Li, Yiling</creator><creator>Jiang, Ting Ting</creator><creator>Jin, Hongchuan</creator><creator>Feng, Lifeng</creator><general>Nature Publishing Group UK</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4506-1213</orcidid></search><sort><creationdate>20201120</creationdate><title>Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies</title><author>Chen, Miaoqin ; Hu, Shiman ; Li, Yiling ; Jiang, Ting Ting ; Jin, Hongchuan ; Feng, Lifeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c512t-1c45640f7b4d93c1370e80b919a434e6b15e27ac6aec00698af268cbfa82c6fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/67/1059</topic><topic>631/67/580</topic><topic>Cancer Research</topic><topic>Cell Biology</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Immunity, Cellular - drug effects</topic><topic>Internal Medicine</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - immunology</topic><topic>Nucleic Acids - immunology</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Review</topic><topic>Review Article</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Miaoqin</creatorcontrib><creatorcontrib>Hu, Shiman</creatorcontrib><creatorcontrib>Li, Yiling</creatorcontrib><creatorcontrib>Jiang, Ting Ting</creatorcontrib><creatorcontrib>Jin, Hongchuan</creatorcontrib><creatorcontrib>Feng, Lifeng</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Signal transduction and targeted therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Miaoqin</au><au>Hu, Shiman</au><au>Li, Yiling</au><au>Jiang, Ting Ting</au><au>Jin, Hongchuan</au><au>Feng, Lifeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies</atitle><jtitle>Signal transduction and targeted therapy</jtitle><stitle>Sig Transduct Target Ther</stitle><addtitle>Signal Transduct Target Ther</addtitle><date>2020-11-20</date><risdate>2020</risdate><volume>5</volume><issue>1</issue><spage>270</spage><epage>270</epage><pages>270-270</pages><artnum>270</artnum><issn>2059-3635</issn><issn>2095-9907</issn><eissn>2059-3635</eissn><abstract>Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibitors. In this review, we summarized the latest discoveries on the combination of nucleic acid-sensing immunity and immune checkpoint inhibitors in cancer immunotherapy. Given the critical role of nuclear acid-mediated immunity in maintaining the activation of T cell function, it seems that harnessing the nuclear acid-mediated immunity opens up new strategies to enhance the effect of immune checkpoint inhibitors for tumor control.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33214545</pmid><doi>10.1038/s41392-020-00347-9</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-4506-1213</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2059-3635 |
| ispartof | Signal transduction and targeted therapy, 2020-11, Vol.5 (1), p.270-270, Article 270 |
| issn | 2059-3635 2095-9907 2059-3635 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7677403 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | 631/67/1059 631/67/580 Cancer Research Cell Biology Humans Immune Checkpoint Inhibitors - therapeutic use Immunity, Cellular - drug effects Internal Medicine Lymphocyte Activation - drug effects Medicine Medicine & Public Health Neoplasms - drug therapy Neoplasms - immunology Nucleic Acids - immunology Oncology Pathology Review Review Article T-Lymphocytes - immunology |
| title | Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T07%3A10%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20nuclear%20acid-mediated%20immunity%20in%20cancer%20immune%20checkpoint%20inhibitor%20therapies&rft.jtitle=Signal%20transduction%20and%20targeted%20therapy&rft.au=Chen,%20Miaoqin&rft.date=2020-11-20&rft.volume=5&rft.issue=1&rft.spage=270&rft.epage=270&rft.pages=270-270&rft.artnum=270&rft.issn=2059-3635&rft.eissn=2059-3635&rft_id=info:doi/10.1038/s41392-020-00347-9&rft_dat=%3Cproquest_pubme%3E2463107384%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2463107384&rft_id=info:pmid/33214545&rfr_iscdi=true |